Marksans Pharma shares surged after Q1FY27 profit jumped 174% YoY to Rs 159 crore. Revenue rose 35.6% to Rs 841 crore, while EBITDA hit a record Rs 213 crore, driven by strong growth in its UK and Europe formulation businesses.
Source :- Markets-Economic Times Read More
